Suppr超能文献

II期精原细胞瘤:为何化疗应维持为标准治疗方案。

Stage II Seminoma: Why Chemotherapy Should Remain a Standard.

作者信息

Naoun Natacha, Bernard-Tessier Alice, Fizazi Karim

机构信息

Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.

出版信息

Eur Urol Open Sci. 2023 Jan 28;49:69-70. doi: 10.1016/j.euros.2022.06.010. eCollection 2023 Mar.

Abstract

Chemotherapy (three cycles of bleomycin + etoposide + cisplatin or four of etoposide + cisplatin) cures the vast majority of stage II seminomas. Retroperitoneal lymph node dissection (RPLND) is safe in early-stage seminoma, but the risk of relapse is not negligible. Long-term chemotherapy side effects are a reality but may be reduced using de-escalation strategies such as in the SEMITEP trial design, motivated by growing interest in survivorship. RPLND may be an option for well-informed select patients who understand that it may be associated with a higher rate of relapse than with cisplatin-based chemotherapy. In any case, local and systemic treatment should not be performed outside high-volume centers.

摘要

化疗(博来霉素+依托泊苷+顺铂三个周期或依托泊苷+顺铂四个周期)可治愈绝大多数II期精原细胞瘤。腹膜后淋巴结清扫术(RPLND)在早期精原细胞瘤中是安全的,但复发风险并非可以忽略不计。长期化疗副作用是现实存在的,但可以通过采用降阶梯策略来降低,比如在SEMITEP试验设计中,这是出于对生存质量关注度的不断提高。对于充分知情且理解RPLND可能比基于顺铂的化疗有更高复发率的特定患者,RPLND可能是一种选择。无论如何,局部和全身治疗不应在非高容量中心进行。

相似文献

1
Stage II Seminoma: Why Chemotherapy Should Remain a Standard.II期精原细胞瘤:为何化疗应维持为标准治疗方案。
Eur Urol Open Sci. 2023 Jan 28;49:69-70. doi: 10.1016/j.euros.2022.06.010. eCollection 2023 Mar.
10
Testicular cancer.睾丸癌
Curr Probl Cancer. 1998 Jul-Aug;22(4):187-274. doi: 10.1016/s0147-0272(98)90012-5.

本文引用的文献

5

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验